National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daratumumab (Darzalex®) for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

NCPE Assessment Process Complete
Rapid review commissioned 09/10/17
Rapid review completed 27/11/17
Rapid Review Outcome A full pharmacoeconomic evaluation is recommended.